Changes in Myocardial Infarction Guideline Adherence as a Function of Patient Risk
- 10 October 2011
- journal article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 58 (17), 1760-1765
- https://doi.org/10.1016/j.jacc.2011.06.050
Abstract
No abstract availableKeywords
Funding Information
- Pfizer Inc.
- Merck/Schering-Plough Partnership
- Accumetrics
- AstraZeneca
- GlaxoSmithKline
- Intekrin Therapeutics
- Merck
- Takeda
- Proventys
- Amylin
- Merck
- Johnson & Johnson
- AstraZeneca
- Bristol-Myers Squibb/Sanofi
- Lilly
- Johnson & Johnson
- Merck/Schering-Plough
- AstraZeneca
- Bristol-Myers Squibb
- Eisai
- Sanofi-Aventis
- The Medicines Company
- Bristol-Myers Squibb/Sanofi
- Merck/Schering-Plough
- Pfizer
- AstraZeneca
This publication has 14 references indexed in Scilit:
- An Organized Approach to Improvement in Guideline Adherence for Acute Myocardial InfarctionArchives of Internal Medicine, 2008
- Translating Evidence Into PracticeArchives of Internal Medicine, 2007
- Exploring the Treatment-Risk Paradox in Coronary DiseaseArchives of Internal Medicine, 2007
- Management Patterns in Relation to Risk Stratification Among Patients With Non–ST Elevation Acute Coronary SyndromesArchives of Internal Medicine, 2007
- A quality guarantee in acute coronary syndromes: The American College of Cardiology's Guidelines Applied in Practice program taken real-timeAmerican Heart Journal, 2007
- The influence of risk status on guideline adherence for patients with non–ST-segment elevation acute coronary syndromesAmerican Heart Journal, 2006
- Guideline-Based Standardized Care Is Associated With Substantially Lower Mortality in Medicare Patients With Acute Myocardial Infarction: The American College of Cardiology’s Guidelines Applied in Practice (GAP) Projects in MichiganJournal of the American College of Cardiology, 2005
- Lipid-Lowering Therapy With Statins in High-Risk Elderly PatientsJAMA, 2004
- Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor TirofibanNew England Journal of Medicine, 2001
- The Treatment and Prevention of Coronary Heart Disease in Canada: Do Older Patients Receive Efficacious Therapies?Journal of the American Geriatrics Society, 1999